Global Viral Vectors for Non-Human Primates Market to Reach USD 429.9 Mn by 2034, Growing at 10.5% CAGR – TMR Analysis

The global viral vectors for non-human primates market was valued at USD 145.8 Mn in 2023 and is projected to grow at a CAGR of 10.5%, reaching over USD 429.9 Mn by 2034. Viral vectors play a crucial role in genetic research, offering efficient tools for gene delivery in various therapeutic and experimental applications. Their significance is increasing in gene therapy, vaccine development, and regenerative medicine, particularly for preclinical studies using non-human primates (NHPs). The market is driven by the expanding scope of gene-modified cell therapies and an increasing number of clinical trials utilizing viral vectors.

Explore the highlights and essential data from our Report in this sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86344

Key Market Drivers

• Surge in Gene and Cell Therapy Research: Rising investment in gene therapy and the development of gene-modified cell therapies such as CAR-T is boosting demand for viral vectors.
• Increasing Use of Non-Human Primates in Preclinical Research: Due to their genetic and physiological similarities to humans, non-human primates remain a critical model for evaluating gene therapies and vaccines.
• Advancements in Viral Vector Technology: Continuous improvements in vector engineering, including enhanced transfection methods, have expanded the potential applications of viral vectors.
• Regulatory Support for Gene Therapies: Favorable regulatory frameworks, including fast-track designations and approvals for gene therapies, are accelerating the adoption of viral vector technologies.

Companies Profiled       

• Lonza
• Thermo Fisher Scientific Inc.
• Revvity
• VectorBuilder Inc.
• Creative Biolabs
• Takara Bio Inc.
• Merck KGaA
• Andelyn Biosciences
• Biovian Oy
• Genezen
• Others Prominent Players

Top Market Trends

1. Advancements in Gene Therapy & Gene-modified Cell Therapies:
• Gene therapy is gaining regulatory approvals at an accelerated pace. In 2023, 10% of U.S. FDA’s innovative drug approvals were cell and gene therapies, indicating strong growth potential.
• CRISPR-based treatments are advancing, with the first U.S. approval granted in late 2023, paving the way for further innovation.
2. Growing Pipeline of Viral Vector-based Therapies:
• Currently, 2,093 gene, cell, and RNA therapies are in R&D, with 35 in phase III clinical trials.
• Over 280 therapies are in phase II trials, while 301 are undergoing phase I evaluation.
• Preclinical research on viral vector-based therapies continues to expand, strengthening the demand for specialized viral vectors tailored for NHP studies.
3. Expanding Applications in Vaccine Research:
• Viral vectors are being increasingly used for vaccine development, including infectious disease research.
• Adeno-associated virus (AAV), lentivirus, and herpes simplex virus are FDA-approved for therapeutic applications, expanding their commercial use.

Access detailed insights by visiting our full report - https://www.transparencymarketresearch.com/viral-vectors-for-non-human-primates-market.html

Market Challenges

• Manufacturing and Scalability Issues: While established players have strong manufacturing capabilities, startups face significant challenges in scaling production.
• High Costs of Viral Vector Development: Production costs remain high due to complex bioprocessing requirements.
• Regulatory Complexities: Strict regulatory guidelines and approval processes for gene therapy-based applications can slow market growth.
• Ethical Concerns Related to Non-Human Primate Research: Increased scrutiny regarding the use of NHPs in research may impact market dynamics.

Segmentation  

Vector Type

• Adenoviral Vectors
• Adeno-associated Vectors
• Retroviral Vectors
• Lentiviral Vectors
• Other Vectors (Baculoviral vectors, etc.)

Type of Non-human Primates

• Marmosets
• Rhesus Macaques
• Cynomolgus Monkey
• Others (Capuchin Monkeys, Chimpanzee, etc.)

Application

• Gene Therapy
• Vaccine Research

Therapeutic Area

• Genetic Disorders
• Infectious Diseases
• Oncological Disorders
• Others

Regions Covered             

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Future Prospects: What’s Next for the Industry?

1. Regional Growth Opportunities:
• North America currently dominates the market, holding approximately 48.3% of the market share in 2023. The U.S. is a hub for biotechnology and pharmaceutical innovation, fostering significant growth in viral vector research.
• Europe and Asia-Pacific are emerging as key markets due to rising investments in gene therapy and growing biotech infrastructure.
2. Collaborations and Acquisitions:
• In May 2024, Merck KGaA acquired Mirus Bio for US$ 600 Mn to strengthen its viral vector production capabilities.
• Takara Bio Inc. entered into a business alliance with Gap Junction Therapeutics in June 2023 to co-develop AAV vector gene therapies for hearing loss.
• Lonza expanded its cell and gene therapy process development labs in the U.S. and Netherlands to support advanced therapy research.
3. Emerging Technologies:
• Advanced gene editing techniques, such as CRISPR and base editing, are expected to further drive demand for viral vectors in research and clinical applications.
• The use of synthetic biology approaches to enhance viral vector production efficiency will play a pivotal role in the industry’s future.

Buy this Premium Research Report for actionable insights and key takeaways – https://www.transparencymarketresearch.com/checkout.php?rep_id=86344&ltype=S

Explore Latest Research Reports by Transparency Market Research:

Carpal Tunnel Release Systems Market: It is projected to grow at a CAGR of 4.9% from 2025 to 2035 and cross US$ 1,036.4 Mn by the end of 2035

Disposable Syringes Market: It is projected to grow at a CAGR of 6.1% from 2025 to 2035 and cross US$ 17,026.2 Mn by the end of 2035

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: sales@transparencymarketresearch.com
Follow Us: LinkedIn| Twitter| Blog | YouTube